| Name | Title | Contact Details |
|---|
As the industry`s largest care access platform Kyruus Health enables our partners to efficiently guide and match people to the care that`s right for them. We create connections across the entire healthcare ecosystem so that every stakeholder can access and harness the most accurate, comprehensive, and contextually relevant information. By enabling informed decisions and confident action, we support healthier outcomes, reduce friction in healthcare, and grant more time back in everyone`s day. At the heart of care access, we connect people to healthcare in a whole new way.
Greater Columbia Behavioral Health is a Kennewick, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rally® believes in putting health care in the hands of individuals with a seamless experience, providing personalized, data-driven information and recommendations that can help improve outcomes and decrease costs for everyone. Rallys Health Solutions help members set personalized daily goals, gives recommendations, and incentivizes progress with rewards. Rallys Care Solutions make health benefits easy to understand and care easy to find on the computer or the Rally app. More than 20 million consumers currently have access to the Rally platform through payers such as UnitedHealthcare, BlueCross BlueShield of South Carolina, and thousands of employer groups. Across offices in Washington, D.C., San Francisco, Chicago, Minneapolis, Denver, and Las Vegas, Rallyers have dedicated themselves to transforming the health care industry for the better—Together.
Infinx Healthcare is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic